These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19170302)

  • 81. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
    Chofflon M; Ben-Amor AF
    Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
    [No Abstract]   [Full Text] [Related]  

  • 82. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
    Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Needle preference in patients receiving cosmetic botulinum toxin type A.
    Price KM; Williams ZY; Woodward JA
    Dermatol Surg; 2010; 36(1):109-12. PubMed ID: 20002642
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Telescopic Dental Needles versus Conventional Dental Needles: Comparison of Pain and Anxiety in Adult Dental Patients of Kerman University of Medical Sciences-A Randomized Clinical Trial.
    Aghahi RH; Nassab SARG; Eskandarizadeh A; Saidi AR; Shahravan A; Hashemipour MA
    J Endod; 2017 Aug; 43(8):1273-1278. PubMed ID: 28578889
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
    Keating MM; Ostby PL
    J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
    [TBL] [Abstract][Full Text] [Related]  

  • 86. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics.
    Jacobs L; Rudick R; Simon J
    J Neuroimmunol; 2000 Jul; 107(2):167-73. PubMed ID: 10854652
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate.
    Masid ML; Ocaña RH; Gil MJ; Ramos MC; Roig ME; Carreño MR; Morales JC; Carrasco ML; Hidalgo LM; Felices AM; Castaño AH; Romero PC; Martinez PF; Sánchez-De la Rosa R
    J Neurosci Nurs; 2015 Feb; 47(1):E22-30. PubMed ID: 25225835
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change.
    Berger BA; Hudmon KS; Liang H
    J Am Pharm Assoc (2003); 2004; 44(4):445-54. PubMed ID: 15372865
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Using Buzzy, Shotblocker, and Bubble Blowing in a Pediatric Emergency Department to Reduce the Pain and Fear Caused by Intramuscular Injection: A Randomized Controlled Trial.
    Yilmaz G; Alemdar DK
    J Emerg Nurs; 2019 Sep; 45(5):502-511. PubMed ID: 31257044
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Shotblocker Use in Emergency Care: A Randomized Clinical Trial.
    Yildirim D; Dinçer B
    Adv Emerg Nurs J; 2021 Jan-Mar 01; 43(1):39-47. PubMed ID: 33952876
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The number of injected same-day preschool vaccines relates to preadolescent needle fear and HPV uptake.
    Baxter AL; Cohen LL; Burton M; Mohammed A; Lawson ML
    Vaccine; 2017 Jul; 35(33):4213-4219. PubMed ID: 28647169
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of the efficacy of ShotBlocker and cold spray in reducing intramuscular injection-related pain in adults. A prospective, randomized, controlled trial.
    Bilge S; Aydin A; Gun C; Aldinc H; Acar YA; Yaylaci S; Cinar O; Balci V
    Saudi Med J; 2019 Oct; 40(10):996-1002. PubMed ID: 31588477
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A Comparison of Two Different Tactile Stimulus Methods on Reducing Pain of Children During Intramuscular Injection: A Randomized Controlled Study.
    Zengin M; Yayan EH
    J Emerg Nurs; 2022 Mar; 48(2):167-180. PubMed ID: 34952709
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efficacy of a Novel Prefilled, Single-Use, Needle-Free Device (Zeneo
    Bardou M; Luu M; Walker P; Auriel C; Castano X
    Adv Ther; 2017 Jan; 34(1):252-260. PubMed ID: 27928757
    [TBL] [Abstract][Full Text] [Related]  

  • 97. ABG needle study: a randomised control study comparing 23G versus 25G needle success and pain scores.
    Yee K; Shetty AL; Lai K
    Emerg Med J; 2015 May; 32(5):343-7. PubMed ID: 24838423
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Influencing Vaccinations: A Buzzy Approach to Ease the Discomfort of a Needle Stick-a Prospective, Randomized Controlled Trial.
    Redfern RE; Micham J; Seegert S; Chen JT
    Pain Manag Nurs; 2019 Apr; 20(2):164-169. PubMed ID: 30425014
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Patient acceptance of Nordiject: a new drug delivery system for growth hormone.
    Jørgensen JT; Mortensen HB; Jørgensen JO
    DICP; 1991 Jun; 25(6):585-8. PubMed ID: 1877265
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparison of a Novel Thin-Walled 25-gauge Needle Push Button Blood Collection Set to a Standard 23-gauge Needle in a Cancer Patient Population.
    Kirchhoff D; Baser R; Kwong D; Ramanathan L; McCash SI
    J Appl Lab Med; 2023 Mar; 8(2):264-271. PubMed ID: 36680315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.